Frequency Therapeutics

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The firm's progenitor cell activation approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. Its product pipeline include Sensorineural hearing loss (FX-322), and Multiple Sclerosis. The company was founded by Robert S. Langer, Jr., David L. Lucchino, Christopher Loose and Will J. McLean on November 13, 2014 and is headquartered in Woburn, MA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass. and LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling treatment of both rare and highly prevalent diseases, today announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. (Frequency; Nasdaq: FREQ) and the entity formerly known as Korro Bio, Inc. (Korro Bio). The combined company will operate under the name Korro Bio, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “KRRO” on November 6, 2023.

UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Frequency Therapeutics, Inc. (NasdaqGS: FREQ) to Korro Bio, Inc. Under the terms of the proposed transaction, pre-merger Frequency Therapeutics stockholders are expected to own approximately 8% of the combined company. KSF is seeking to determine whether this consideration and the process that led to it are ad.

FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023. In July, the Company announced that it entered into a definitive merger agreement with Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines. After the anticipated consummation of the merger, the combined company will operate under Korro Bio, Inc. with a focus.

Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results

Post-merger, Frequency (FREQ) focuses on advancing RNA editing programs. This combined entity is set to operate under the name Korro Bio, which will apply to trade on the NASDAQ under the ticker symbol KRRO.

Frequency (FREQ) Up 77% on Merger Deal With Korro Bio

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Frequency Therapeutics, Inc. (NASDAQ: FREQ) and Korro Bio, Inc. is fair to Frequency shareholders. Pre-merger Frequency shareholders are expected to own approximately 8% of the combined company. Halper Sadeh encourages Frequency shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersade.

FREQ Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Frequency Therapeutics, Inc. Is Fair to Shareholders

Frequency Therapeutics (NASDAQ: FREQ ) stock is rocketing higher on Friday following news that it will combine with Korro Bio . This merger plan is designed to bring Korro Bio public and will focus on the development of its RNA editing programs.

Why Is Frequency Therapeutics (FREQ) Stock Up 44% Today?

CAMBRIDGE & LEXINGTON, Mass.--(BUSINESS WIRE)--Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Korro Bio's portfolio of RNA editing programs, is expected to operate under Korro Bio, Inc. and will apply.

Korro Bio and Frequency Therapeutics Announce Merger Agreement

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2023. “We are pleased with the team's progress in advancing our program for remyelination in multiple sclerosis and we remain on track to commence our clinical program in the first half of 2024. We.

Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2022.

Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced that interim Chief Executive Officer and Chief Scientific Officer Christopher Loose, Ph.D., will present at the following March healthcare investor conferences: 43rd Annual Cowen Healthcare Conference: Dr. Loose will participate on a panel discussion on March 8th at 12:50 p.

Frequency Therapeutics to Participate at Upcoming March Investor Conferences

Detailed research on the small animal imaging in vivo market is just released by SkyQuest. Using cutting-edge analytical methods and methodology, this study delivers a thorough industry analysis and a full insight into the market landscape. The research also discusses a variety of subjects, such as market trends, important companies, product advancements, investment strategies, and more. Detailed research on the small animal imaging in vivo market is just released by SkyQuest. Using cutting-edge analytical methods and methodology, this study delivers a thorough industry analysis and a full insight into the market landscape. The research also discusses a variety of subjects, such as market trends, important companies, product advancements, investment strategies, and more.

Small Animal Imaging In Vivo Market is Anticipated to Reach a Value of USD 6.1 Billion by Growing at a CAGR of 8.89% During 2022-2028; Expanding Healthcare Sector and Rising Clinical Research to Elevate Market Growth

The stock price of Frequency Therapeutics Inc (NASDAQ: FREQ) plummeted 80.54% in the most recent trading session. This is why.

FREQ Stock: 80.54% Plummet Explanation

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss (SNHL).

Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

LEXINGTON, Mass.--( BUSINESS WIRE )--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced that it has established a Clinical Advisory Board to help guide its remyelination in multiple sclerosis (MS) program. Comprised of leading experts from across the neurosciences, the Clinical Advisory Board will support clinical development and translation efforts as the Company advances its small molecule therapeutic candidate through human studies. The Company plans a regulatory filing for its remyelination program in the second half of 2023.

Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program

LEXINGTON, Mass.--( BUSINESS WIRE )--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced that it has dosed a first patient in the Phase 1b study of FX-345, the Company's second hearing restoration candidate for sensorineural hearing loss (SNHL).

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company's Second Therapeutic Candidate for Sensorineural Hearing Loss

NEW YORK , Nov. 29, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Frequency Therapeutics, Inc. (NASDAQ: FREQ). If you are a shareholder of Frequency Therapeutics, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/frequency-therapeutics-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Frequency Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

LEXINGTON, Mass.--( BUSINESS WIRE )--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced that it will host a virtual investor event on December 13, 2022, with a focus on FX-322, the Company's lead hearing restoration candidate for acquired sensorineural hearing loss (SNHL). A Phase 2b study of FX-322 (FX-322-208) is fully enrolled with clinical results anticipated in the first quarter of 2023.

Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results

Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results

Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced that members of its management team will participate in investor and medical conferences later this month. HC Wainwright 24th Annual Global Investment Conference: Company overview presentation by David Lucchino, CEO, Tuesday, September 13, 2022, 11 a.m. EST Am

Frequency Therapeutics to Participate in September Investor and Medical Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced business updates and financial results for the second quarter ended June 30, 2022. “I am very pleased with our team's pipeline execution and the clear progress across all of our clinical and pre-clinical programs. We have reached a predictable cadence in our F

Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results

Frequency Therapeutics, Inc. (FREQ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock?

Wilmington, Delaware--(Newsfile Corp. - May 18, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Frequency Therapeutics, Inc. (NasdaqGS: FREQ) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-frequency-therapeutics-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Frequency Therapeutics, Inc.

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Christopher Loose will present at the upcoming H.C. Wainwright Global Investment Conference. Dr. Loose's presentation will be available to view beginning at 7:00 a.m. ET on May 24th and may be accessed on the inve

News for Frequency Therapeutics Stock (FREQ)